6886.TWO Far East Bio-Tec Co., Ltd.
- Market cap
- TWD 1.35B
- P/E
- 21.8x
- P/B
- 2.30x
- ROE
- 10.2%
- Dividend yield
- 2.23%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6886.TWO undervalued?
Graham number6886.TWO trades 49.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Far East Bio-Tec Co., Ltd. fundamental analysis
No fundamental analysis for Far East Bio-Tec Co., Ltd. yet.
Far East Bio-Tec Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Far East Bio-Tec Co., Ltd.
Far East Bio-Tec Co., Ltd. manufactures and sells organic chlorella, spirulina, and dietary supplements. It also offers nutraceuticals/nutritional supplements, immune booster products, antiviral sprays, and pet supplements. The company was founded in 1976 and is based in Taipei, Taiwan.
Full company profileFar East Bio-Tec Co., Ltd. financial statements
Far East Bio-Tec Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 293M | 319M | 380M | 306M | 388M | 402M |
| Gross Profit | 136M | 142M | 215M | 142M | 187M | 203M |
| Operating Income | 34.0M | 39.6M | 109M | 28.5M | 64.1M | 68.6M |
| EBITDA | 54.9M | 58.0M | 127M | 49.1M | 90.3M | 98.9M |
| Net Income | 39.8M | 32.9M | 90.7M | 27.4M | 52.5M | 60.0M |
| EPS | 1.30 | 1.11 | 3.62 | 0.95 | 1.79 | 1.72 |
| Balance Sheet | ||||||
| Total Assets | 486M | 464M | 546M | 569M | 641M | 702M |
| Total Liabilities | 95.9M | 97.9M | 114M | 80.9M | 128M | 114M |
| Shareholders' Equity | 388M | 366M | 432M | 489M | 514M | 588M |
| Cash & Short-term Investments | 276M | 253M | 318M | 322M | 278M | 272M |
| Total Debt | 51.9M | 48.3M | 47.6M | 37.7M | 68.8M | - |
| Cash Flow | ||||||
| Operating Cash Flow | 75.9M | 53.7M | 107M | -2.09M | 76.9M | 48.8M |
| Capital Expenditure | 9.98M | 7.11M | 11.2M | 15.5M | 87.1M | 60.4M |
| Free Cash Flow | 65.9M | 46.6M | 95.6M | -17.6M | -10.2M | -11.5M |
| Ratios | ||||||
| ROE | 10.2% | 9.0% | 21.0% | 5.6% | 10.2% | 10.2% |
| ROA | 8.2% | 7.1% | 16.6% | 4.8% | 8.2% | 8.5% |
| Net Profit Margin | 13.6% | 10.3% | 23.9% | 8.9% | 13.5% | 14.9% |
| Debt to Equity | 0.13x | 0.13x | 0.11x | 0.08x | 0.13x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Far East Bio-Tec Co., Ltd. dividends
- Dividend yield
- 2.23%
- Forward dividend
- 0.50 TWD
- Payout ratio
- 50.3%
- Ex-dividend date
- Aug 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 30.2M | 0.86 | 50.3% |
| 2024 | TWD 27.8M | 0.95 | 53.0% |
| 2023 | TWD 75.1M | 2.60 | 274.0% |
| 2022 | TWD 25.0M | 1.00 | 27.6% |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1100:1000 on Aug 28, 2026.
Who owns Far East Bio-Tec Co., Ltd.
Ownership data of Far East Bio-Tec Co., Ltd. is not available yet.
Far East Bio-Tec Co., Ltd. company profile
- Company name
- Far East Bio-Tec Co., Ltd.
- Ticker
- 6886.TWO
- ISIN
- TW0006886005
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Fiscal year end
- December
- Address
- Room A, Taipei, Taiwan, 115
- Phone
- 886 2 2655 8198
- Website
- febico.com
About Far East Bio-Tec Co., Ltd.
Far East Bio-Tec Co., Ltd. manufactures and sells organic chlorella, spirulina, and dietary supplements. It also offers nutraceuticals/nutritional supplements, immune booster products, antiviral sprays, and pet supplements. The company was founded in 1976 and is based in Taipei, Taiwan.
Far East Bio-Tec Co., Ltd. management
1- Mr. C. C. ChiuehFounder & CEO